Longevity Scientist: Can This Supplement Really Reverse Aging?

Mark walked through the entire science of urolythin A: its discovery as a by‑product of ellagic acid from pomegranates, the critical role of specific gut bacteria (only 10‑40% of Western populations harbour them), and its ability to turn damaged mitochondria into functional ones. In placebo‑controlled trials, even sedentary older adults saw ~10–12% strength gains, ~10% V2 max improvements, and lower CRP and cytokine levels without changing diet or exercise. The effect follows a time‑course: one month—cellular shift (fewer damaged mtDNA, more PGC1α); two months—physiological changes (peak V2 max); four months—measurable strength and endurance gains. Mark stresses that this compound acts on the same pathways as exercise and fasting, but it must be used as part of a foundation of good diet and movement, not as an isolated magic bullet.

Mark repeatedly calls exercise “the best mitochondrial drug.” He references multiple studies showing that 70‑ and 80‑year‑olds who exercise have far healthier mitochondria than those who are sedentary. Dr. Singh adds that even in research, every intervention that improves mitochondrial health—whether in overweight individuals, the elderly, or overtrained athletes—also lowers inflammation. Mark draws on his functional medicine experience, noting that V2 max testing (an indirect measure of mitochondrial function) is a strong predictor of longevity: the higher your V2 max, the longer you live. He explains that exercise both creates new mitochondria (biogenesis) and helps clear damaged ones (mitophagy), hitting the same pathways as rapamycin, metformin, and intermittent fasting, but without the side effects.

Mark frames protein as a critical but overlooked mitochondrial intervention. He references Dr. Don Layman’s work on anabolic resistance and explains that most older adults eat 40 grams less protein than they need. Dr. Singh adds that high‑protein supplementation is already being combined with mitochondrial interventions like urolythin A in trials to boost muscle quality. Mark underscores the superiority of animal protein for leucine, the key amino acid for mTOR‑driven muscle synthesis, and ties this to his own dramatic muscle regain at 65 after a health crisis. He dispels the myth that plant‑based diets can easily match these requirements without excessive calories.

Mark notes that he personally uses MCT oil before bike rides to maintain endurance and metabolic function. He links this to the broader theme that ketogenic diets—by shifting fuel preference from glucose to fat—dramatically benefit mitochondrial diseases like autism, Alzheimer’s, bipolar disorder, and type 2 diabetes. Dr. Singh confirms that ketones rev up mitochondria, which prefer fat as a source, and that studies show ketogenic diets outperform current therapies for several mitochondrial‑based conditions. Mark therefore positions MCT oil as a practical, readily available way to deliver ketones and support mitochondrial health during exercise.

Mark expresses alarm that most physicians never check mitochondrial function and that even asymptomatic statin users show significant mitochondrial pathology on biopsy. He states unequivocally that CoQ10 supplementation is mandatory for statin users, though he acknowledges its limited bioavailability and questions whether it can truly protect the mitochondrial network. Dr. Singh adds that statins deplete the electron transport chain and can cause rhabdomyolysis, a severe muscle‑breakdown syndrome. Both agree that a trial combining a statin with a mitophagy agent would be valuable but is difficult to conduct due to regulatory hurdles. This reinforces Mark’s broader call for a “360 approach” that includes clearing damaged mitochondria alongside direct mitochondrial support.

Towards the conclusion, Mark brings up sauna as a less‑discussed mitochondrial strategy, citing evidence that regular sauna use improves cardiovascular and metabolic health. Dr. Singh adds that cold exposure research by a collaborator suggests that living in colder environments is better for mitochondria, and that sauna and red light therapy are promising augmentative tools. Both advocate a multi‑modal approach, integrating these therapies with nutrition and supplements to build a robust mitochondrial “marathon” approach.

Mark Hyman dives into the discovery that pomegranate‑derived ellagic acid is converted by specific gut bacteria into urolithins, with urolythin A being the most potent. The guest researcher explains that across populations, only 10–40% of people harbour the right microbes, a number that plummets to 5% in regions with heavy antibiotic use. The molecule was originally thought a waste product but turned out to be a powerful mitophagy activator, acting like “super Pac‑Man” to clear damaged mitochondria. In placebo‑controlled trials, sedentary older adults taking 500–1000 mg daily showed cellular improvements (increased PGC1α, fewer damaged mitochondrial DNA) at one month, physiological changes like higher V2 max at two months, and tangible strength gains by four months—all without lifestyle changes. Mark emphasises this is not a magic pill but a “third pillar” alongside diet and exercise, working through the same PGC1α pathway as regular training.

Mark emphasises that early studies showed “even without any muscle pain even without an abnormal blood test … pretty much everybody on a statin if you do a muscle biopsy has damaged mitochondria.” He finds this deeply worrying because mitochondrial health is central to aging and disease. He recommends that anyone on a statin must take CoQ10, though he concedes that CoQ10 alone may not fully reverse the damage because of poor bioavailability. He also speculates that clearing damaged mitochondria with mitophagy enhancers like urolythin A could be necessary to truly protect against statin‑induced mitochondrial decline. Dr. Singh adds that statins deplete the electron transport chain and CoQ10, and that muscle side effects can progress to rhabdomyolysis. Both express concern that other commonly used drugs—like corticosteroids and GLP‑1 agonists—may also harm mitochondria, though evidence is still emerging.

Mark shares that as a 65‑year‑old, he gained back not only the lost weight but an additional 5 lbs of muscle, arriving at a condition more “ripped” than he was at 40. He attributes this to disciplined strength training (which he hadn’t done earlier in life) and a high‑protein diet. He uses this as a proof of concept that “muscle is a sponge … it just needs a little stimulus to get it going.” The story underpins his broader message that mitochondrial and muscular plasticity persists into advanced age, and that many of the declines we attribute to aging are actually the result of accumulated mitochondrial damage and under‑stimulation—both of which can be corrected. This aligns with the research on sarcopenia and mitochondrial dysfunction, where even 70‑year‑olds who exercise have far healthier mitochondria than their sedentary peers.